Men with nonmetastatic, hormone-sensitive prostate cancer experience the greatest average change in bone mineral density (BMD) during the early treatment period of intermittent androgen deprivation (IAD) and fractures are rare.
Taking both metformin and statins significantly reduces the incidence of prostate cancer
Metformin may improve prostate-specific antigen levels and slow cancer growth.
The oral small-molecule galeterone (TOK-001) was safe and led to a decline in prostate-specific antigen (PSA) expression in chemotherapy-naïve patients with castration-resistant prostate cancer (CRPC), results of a Phase I trial presented during the AACR Annual Meeting 2012 in Chicago, IL, have found.
Adding bevacizumab to docetaxel and prednisone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) did not improve overall survival and was associated with greater toxicity, despite an improvement in progression-free survival and objective response.
An enzyme that balances the use of glucose for energy generation with the synthesis of antioxidants is important for the growth and survival of prostate cancer.
Screening men for prostate-specific antigen (PSA) levels significantly reduces their risk of death from prostate cancer, but not their overall risk of death.
Investigators have characterized how pro-invasion messenger RNAs direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling — and then developed a clinically relevant ATP site inhibitor of mTOR, INK128, “which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure,” they noted in Nature, published online February 22.
The U.S. Food and Drug Administration has approved PROGENSA PCA3, “the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy,” according to the assay’s manufacturer, Gen-Probe, San Diego, CA.
A significant correlation between coronary artery disease (CAD) and prostate cancer (PCa) has been found among men participating in a prostate drug trial.
